Technical Analysis for ESPR - Esperion Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 9.14 | -1.72% | -0.16 |
ESPR closed down 1.72 percent on Friday, October 15, 2021, on approximately normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
Earnings due: Nov 2
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Down |
| Historical ESPR trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| New 52 Week Low | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| New 52 Week Closing Low | Bearish | -1.72% | |
| Volume Surge | Other | -1.72% | |
| New 52 Week Low | Weakness | -1.72% | |
| Multiple of Ten Bearish | Other | -1.72% | |
| Wide Bands | Range Expansion | -1.72% | |
| Gapped Down | Weakness | -1.72% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Fell Below Previous Day's Low | 3 days ago |
| Down 1% | 3 days ago |
| New 52 Week Low | 3 days ago |
| Possible NR7 | 3 days ago |
| Possible Inside Day | 3 days ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/02/2021
Esperion Therapeutics, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of therapies for the treatment of patients with low-density lipoprotein cholesterol and other cardiometabolic risk factors. Its products include ETC-1002, an oral molecule therapy that is in Phase IIa clinical trials to treat lipid and carbohydrate metabolic pathways; ESP41091, which is in pre-clinical trials for type 2 diabetes and obesity treatment; and 4WF, a synthetic therapy that is in pre-clinical trials to reverse the deleterious effects of atherosclerosis. The company is based in Plymouth, Michigan.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Diabetes Lipid Cardiology Obesity Cholesterol Lipoprotein Lipids Gabaa Receptor Positive Allosteric Modulators Low Density Lipoprotein Niacin Atherosclerosis Lipoproteins
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Diabetes Lipid Cardiology Obesity Cholesterol Lipoprotein Lipids Gabaa Receptor Positive Allosteric Modulators Low Density Lipoprotein Niacin Atherosclerosis Lipoproteins
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 39.495 |
| 52 Week Low | 9.1001 |
| Average Volume | 764,825 |
| 200-Day Moving Average | 21.94 |
| 50-Day Moving Average | 12.32 |
| 20-Day Moving Average | 11.22 |
| 10-Day Moving Average | 10.21 |
| Average True Range | 0.68 |
| ADX | 30.21 |
| +DI | 12.20 |
| -DI | 32.88 |
| Chandelier Exit (Long, 3 ATRs) | 11.11 |
| Chandelier Exit (Short, 3 ATRs) | 11.13 |
| Upper Bollinger Bands | 13.51 |
| Lower Bollinger Band | 8.93 |
| Percent B (%b) | 0.05 |
| BandWidth | 40.86 |
| MACD Line | -0.86 |
| MACD Signal Line | -0.72 |
| MACD Histogram | -0.1402 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 9.72 | ||||
| Resistance 3 (R3) | 9.78 | 9.63 | 9.63 | ||
| Resistance 2 (R2) | 9.63 | 9.48 | 9.61 | 9.59 | |
| Resistance 1 (R1) | 9.39 | 9.39 | 9.32 | 9.33 | 9.56 |
| Pivot Point | 9.24 | 9.24 | 9.21 | 9.22 | 9.24 |
| Support 1 (S1) | 9.00 | 9.09 | 8.93 | 8.95 | 8.72 |
| Support 2 (S2) | 8.85 | 9.00 | 8.83 | 8.69 | |
| Support 3 (S3) | 8.61 | 8.85 | 8.65 | ||
| Support 4 (S4) | 8.56 |
